Abstract |
Hodgkin lymphoma (HL) can be aggressive and intractable in some cases. Patients who relapse after autologous HCT (auto-HCT) have limited treatment options. City of Hope reports our experience in the use of reduced intensity allogeneic hematopoietic cell transplantation (allo-HCT) in 24 heavily pretreated patients with relapsed HL, between January 2003 and December 2008. The median number of prior therapies was 5; 20/24 patients had prior auto-HCT. The conditioning regimen for all patients was fludarabine and melphalan. With a median follow-up for living patients of 39.0 months, at 2 years the overall survival (OS) was 60% (95% CI 42, 72) and the progression-free survival was 27% (95% CI 22, 32). Non-relapse mortality was 13.1% (95% CI 5.1, 31.4) at 2 years. The incidence of grade II-IV aGVHD was 45.8% and 8.3% for grade III-IV. Allo-HCT in heavily pretreated relapsed Hodgkin lymphoma is feasible, tolerable, and can induce durable clinical remissions.
|
Authors | Robert Chen, Joycelynne M Palmer, Leslie Popplewell, Jessica Shen, Eileen Smith, Maria Delioukina, Neil Kogut, Joseph Rosenthal, Stephen Forman, Auayporn Nademanee |
Journal | Annals of hematology
(Ann Hematol)
Vol. 90
Issue 7
Pg. 803-8
(Jul 2011)
ISSN: 1432-0584 [Electronic] Germany |
PMID | 21210120
(Publication Type: Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Myeloablative Agonists
- Vidarabine
- fludarabine
- Melphalan
|
Topics |
- Adolescent
- Adult
- Antineoplastic Agents
(therapeutic use)
- Clinical Trials as Topic
- Disease Progression
- Disease-Free Survival
- Female
- Graft vs Host Disease
(prevention & control)
- Hematopoietic Stem Cell Transplantation
(methods)
- Hodgkin Disease
(drug therapy, prevention & control, surgery)
- Humans
- Male
- Melphalan
(therapeutic use)
- Middle Aged
- Myeloablative Agonists
(therapeutic use)
- Recurrence
- Transplantation Conditioning
- Transplantation, Homologous
(methods)
- Treatment Outcome
- Vidarabine
(analogs & derivatives, therapeutic use)
- Young Adult
|